<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, July 9, 2018 (HealthDay News) — For postmenopausal African-American women, high-risk APOL1<\/i> genotype seems not to be associated with coronary heart disease, stroke, or mortality, according to a study published online July 3 in JAMA Cardiology<\/i>.<\/p>\n
Nora Fransceschini, M.D., M.P.H., from the University of North Carolina in Chapel Hill, and colleagues used data from the Women’s Health Initiative to examine whether high-risk APOL1<\/i> genotypes are associated with cardiovascular disease and stroke in postmenopausal African-American women. APOL1<\/i> variants were genotyped or imputed from whole-exome sequencing.<\/p>\n
The researchers found that high-risk APOL1<\/i> variant carriers had increased prevalence of hypertension, use of cholesterol-lowering medications, and reduced estimated glomerular filtration rate (eGFR). Carriers of high-risk APOL1<\/i> variants had increased incidence of hospitalized heart failure with preserved ejection fraction (HFpEF) compared with low-risk carriers after a mean of 11 years; no differences were seen for other outcomes. A significantly increased hazard of hospitalized HFpEF was seen among carriers of high-risk versus low-risk APOL1<\/i> variants in adjusted models (hazard ratio, 1.58; 95 percent confidence interval, 1.03 to 2.41). After adjustment for baseline eGFR, the correlation with HFpEF was attenuated and no longer significant (hazard ratio, 1.5; 95 percent confidence interval, 0.98 to 2.3).<\/p>\n
“These findings do not support an association of high-risk APOL1<\/i> genotypes with coronary heart disease, stroke, or mortality in postmenopausal African-American women,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n